Partnering with China to improve health worldwide
PATH’s trusted relationships in China date back to our earliest efforts as an organization. Since 1979, we have collaborated with government agencies, nongovernmental organizations, research institutes, and manufacturers throughout the country to improve health and save lives.
Our first projects focused on increasing access to modern contraception. Today, we work on maternal and child health, adolescent health, HIV, tuberculosis (TB), and vaccines and immunization. In addition, PATH’s manufacturing partnerships and technical assistance in China are having a remarkable health impact, both inside China and beyond its borders. Today, the country is a leading supplier of lifesaving health technologies and products for low-resource settings worldwide.
Our work in China
Tuberculosis: PATH is part of a collaborative effort to address China’s high burden of TB and multidrug-resistant TB by developing and demonstrating effective, comprehensive TB control models using innovative tools and approaches. We are helping to strengthen the Chinese health system, evaluating the use of new diagnostic tools and delivery approaches, identifying unmet needs, and coordinating experts to close gaps. Together, these projects serve a combined population of nearly 100 million people.
Vaccines: PATH partners with Chinese vaccine developers and manufacturers to bring safe and affordable vaccines to families worldwide. Our technical support reaches from early stage vaccine testing to manufacture and regulation. For example, we supported the Chengdu Institute of Biological Products to produce a vaccine against Japanese encephalitis. It was the first vaccine from a Chinese manufacturer to achieve prequalification by the World Health Organization (WHO), marking China’s entrance into the global vaccine marketplace. Today, the vaccine is protecting millions of people across Asia and the Western Pacific.
PATH is now partnering to increase production of an affordable bivalent oral polio vaccine and to develop a new oral vaccine against rotavirus, a leading cause of deadly diarrhea. We are also supporting Chinese manufacturers to achieve WHO prequalification of vaccines against human papillomavirus (HPV), the primary cause of cervical cancer.
Diagnostics and drugs: PATH is collaborating with Chinese and global partners to develop, advance, and manufacture a new DNA-based diagnostic for HPV. We also lead an international consortium to advance the use of a potentially groundbreaking new drug, called tribendimidine, to treat infection from parasitic worms known as soil-transmitted helminths.
Devices for reproductive and child health: Our work to make health devices and tools available and affordable worldwide has long been supported by our collaboration with Chinese manufacturers. Innovations produced with Chinese partners include household water treatment products, the Woman’s Condom, and the lifesaving Nifty Feeding Cup, a simple, handheld cup that allows infants who cannot breastfeed to lap breast milk.
Photo: Courtesy of Bill & Melinda Gates Foundation/Lou Linwei.
An overview of our work in China
PATH’s work on Japanese encephalitis helps millions get access to a lifesaving vaccine
Helping women take charge of their own protection